Sandro Ardizzone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2353909/publications.pdf

Version: 2024-02-01

186 papers 13,480 citations

23567 58 h-index 23533 111 g-index

190 all docs 190 docs citations

190 times ranked

11574 citing authors

#	Article	IF	CITATIONS
1	Prevalence and significance of mesentery thickening and lymph nodes enlargement in Crohn's disease. Digestive and Liver Disease, 2022, 54, 490-499.	0.9	9
2	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. Clinical Gastroenterology and Hepatology, 2022, 20, 2741-2752.e6.	4.4	18
3	Repeated surgery for recurrent Crohn's disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures. Updates in Surgery, 2022, 74, 73-80.	2.0	7
4	Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut, 2022, 71, 1926-1928.	12.1	14
5	Impact of the COVID-19 Outbreak on Anesthesiologist Assistance for Endoscopic Procedures. Clinical Endoscopy, 2022, 55, 49-57.	1.5	1
6	Stem Cell Injection for Complex Refractory Perianal Fistulas in Crohn's Disease: A Single Center Initial Experience. Frontiers in Surgery, 2022, 9, 834870.	1.4	2
7	Has the Removing of the Mesentery during Ileo-Colic Resection an Impact on Post-Operative Complications and Recurrence in Crohn's Disease? Results from the Resection of the Mesentery Study (Remedy). Journal of Clinical Medicine, 2022, 11, 1961.	2.4	3
8	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.9	22
9	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. Journal of Clinical Medicine, 2022, 11, 2302.	2.4	25
10	Gastrointestinal tuberculosis presenting as acute abdomen: a case report. Journal of Surgical Case Reports, 2022, 2022, .	0.4	2
11	Pathophysiology and therapeutic management of anemia in gastrointestinal disorders. Expert Review of Gastroenterology and Hepatology, 2022, 16, 625-637.	3.0	0
12	Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Digestive and Liver Disease, 2021, 53, 263-270.	0.9	23
13	Ultrasonographic Evaluation of Intestinal Fibrosis and Inflammation in Crohn's Disease. The State of the Art. Frontiers in Pharmacology, 2021, 12, 679924.	3 . 5	5
14	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Therapeutics and Clinical Risk Management, 2021, Volume 17, 285-292.	2.0	4
15	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Frontiers in Immunology, 2021, 12, 656362.	4.8	29
16	Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn's disease-associated small bowel carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 667-678.	2.8	10
17	Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clinical Gastroenterology and Hepatology, 2021, 19, 2293-2301.e1.	4.4	3
18	Lower incidence of COVIDâ€19 in patients with inflammatory bowel disease treated with nonâ€gut selective biologic therapy. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3050-3055.	2.8	16

#	Article	IF	Citations
19	Strictureplasties performed by laparoscopic approach for complicated Crohn's disease. A prospective, observational, cohort study. Digestive and Liver Disease, 2021, 53, 1286-1293.	0.9	7
20	Anti-tumour necrosis factor \hat{l}_{\pm} antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. International Immunopharmacology, 2021, 100, 108081.	3.8	0
21	Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's and Colitis, 2020, 14, 295-302.	1.3	14
22	Abdominal Symptoms and Colonic Diverticula in Marfan's Syndrome: A Clinical and Ultrasonographic Case Control Study. Journal of Clinical Medicine, 2020, 9, 3141.	2.4	1
23	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmunity Reviews, 2020, 19, 102574.	5.8	32
24	The impact of covid-19 pandemic on urgent endoscopy in Italy: a nation-wide multicenter study. Scandinavian Journal of Gastroenterology, 2020, 55, 870-876.	1.5	35
25	Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacological Research, 2020, 161, 105206.	7.1	22
26	Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 203-213.	0.9	13
27	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	1.9	51
28	Noninvasive testing in the management of children with suspected inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 586-591.	1.5	14
29	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
30	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease  AGED' study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	1.6	14
31	Use, effectiveness and tolerability of budesonideâ€MMX in ulcerative colitis: A realâ€life experience. United European Gastroenterology Journal, 2019, 7, 1164-1170.	3.8	9
32	Comprehensive review on EUS-guided biliary drainage. World Journal of Gastrointestinal Endoscopy, 2019, 11, 354-364.	1.2	30
33	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. Journal of Crohn's and Colitis, 2018, 12, 476-488.	1.3	43
34	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.9	22
35	Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases. International Immunopharmacology, 2018, 54, 329-335.	3.8	8
36	Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy, 2018, 19, 1747-1757.	1.8	11

#	Article	IF	Citations
37	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ⁻ve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	1.9	56
38	Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. Digestive and Liver Disease, 2018, 50, 1283-1291.	0.9	15
39	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.9	42
40	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.9	47
41	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	1.3	1,324
42	The PROSIT-BIO Cohort. Inflammatory Bowel Diseases, 2017, 23, 233-243.	1.9	116
43	Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. Journal of Crohn's and Colitis, 2017, 11, 942-953.	1.3	51
44	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 399-406.	8.1	70
45	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn's and Colitis, 2017, 11, 135-149.	1.3	558
46	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study― Digestive and Liver Disease, 2017, 49, 17-23.	0.9	35
47	Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Thrombosis and Haemostasis, 2016, 116, 486-495.	3.4	29
48	Endoscopic full-thickness resection of a submucosal right colon lesion. Endoscopy, 2016, 48, E376-E377.	1.8	5
49	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	1.3	30
50	Impact of patient characteristics on the clinical efficacy of mongersen (GEDâ€0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 717-724.	3.7	35
51	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.9	34
52	Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease. Therapeutic Advances in Gastroenterology, 2016, 9, 527-532.	3.2	37
53	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578.	1.3	251
54	Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2137-2144.	1.9	32

#	Article	IF	CITATIONS
55	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	7.4	136
56	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	27.0	366
57	Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World Journal of Gastroenterology, 2014, 20, 3507.	3 . 3	35
58	Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. International Journal of Colorectal Disease, 2014, 29, 1285-1290.	2.2	36
59	Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries. Inflammatory Bowel Diseases, 2014, 20, 936-945.	1.9	129
60	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1146-1151.	1.6	26
61	Small Bowel Adenocarcinomas Complicating Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease Are Associated With Dysplasia. Inflammatory Bowel Diseases, 2014, 20, 1584-1592.	1.9	7 5
62	ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior. Journal of Crohn's and Colitis, 2014, 8, 489-494.	1.3	32
63	Pneumatosis intestinalis and perforation in Crohn's disease: Worrisome or not?. Journal of Crohn's and Colitis, 2014, 8, 338-339.	1.3	4
64	Rheumatic manifestations in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 20-23.	5 . 8	61
65	Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2014, 15, 1659-1670.	1.8	14
66	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). Journal of Crohn's and Colitis, 2014, 8, 5-18.	1.3	110
67	Serum protein profiling of early and advanced stage Crohn's disease. EuPA Open Proteomics, 2014, 3, 48-59.	2.5	23
68	Immunity, autoimmunity and inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 1-2.	5.8	28
69	Crohn's Disease Loci Are Common Targets of Protozoa-Driven Selection. Molecular Biology and Evolution, 2013, 30, 1077-1087.	8.9	28
70	The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis and Tissue Repair, 2013, 6, 13.	3.4	82
71	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.9	72
72	Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmunity Reviews, 2013, 12, 703-708.	5 . 8	167

#	Article	IF	CITATIONS
73	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's and Colitis, 2013, 7, 556-585.	1.3	541
74	PillCam Colon and ulcerative colitis: what do physicians need to know?. Endoscopy, 2013, 45, 325-325.	1.8	7
75	Transperineal Perineal Ultrasound Versus Magnetic Resonance Imaging In the Assessment of Perianal Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2737-2743.	1.9	55
76	Role of the advanced glycation end products receptor in Crohn's disease inflammation. World Journal of Gastroenterology, 2013, 19, 8269.	3.3	31
77	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	2.4	256
78	Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs, 2012, 17, 449-467.	2.4	18
79	Portal vein thrombosis in inflammatory bowel diseases: A single-center case series. Journal of Crohn's and Colitis, 2012, 6, 362-367.	1.3	37
80	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	4.4	316
81	Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2011, 9, 483-489.e3.	4.4	242
82	Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn's and Colitis, 2011, 5, 477-483.	1.3	310
83	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseasea † Digestive and Liver Disease, 2011, 43, 1-20.	0.9	125
84	Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Digestive and Liver Disease, 2011, 43, 535-541.	0.9	41
85	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease, 2011, 43, 946-952.	0.9	53
86	Endoscopic Palliation in Patients With Incurable Malignant Colorectal Obstruction by Means of Self-expanding Metal Stent. Archives of Surgery, 2011, 146, 1157.	2.2	104
87	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Alimentary Pharmacology and Therapeutics, 2011, 34, 724-734.	3.7	146
88	Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Alimentary Pharmacology and Therapeutics, 2011, 34, 1088-1097.	3.7	29
89	Cancer in Crohn $\hat{E}\frac{1}{4}$ s Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflammatory Bowel Diseases, 2011, 17, 758-766.	1.9	41
90	An Evolutionary Analysis of RAC2 Identifies Haplotypes Associated with Human Autoimmune Diseases. Molecular Biology and Evolution, 2011, 28, 3319-3329.	8.9	19

#	Article	IF	Citations
91	Vitamin D and Inflammatory Bowel Disease. Vitamins and Hormones, 2011, 86, 367-377.	1.7	35
92	Peripheral regulatory T cells and serum transforming growth factor- \hat{l}^2 : Relationship with clinical response to infliximab in Crohn $\hat{\mathbb{L}}_4$ s disease. Inflammatory Bowel Diseases, 2010, 16, 1891-1897.	1.9	40
93	Review: Immunomodulators for all patients with inflammatory bowel disease?. Therapeutic Advances in Gastroenterology, 2010, 3, 31-42.	3.2	27
94	To Stent or Not to Stent?: Palliative Management of Inoperable Colorectal Cancer. American Journal of Gastroenterology, 2010, 105, 1209.	0.4	1
95	Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-A treatment. Haematologica, 2010, 95, 199-205.	3.5	140
96	Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study. American Journal of Gastroenterology, 2010, 105, 1150-1157.	0.4	110
97	Is mucosal healing a predictor of decreased risk of Crohn's disease relapse after withdrawal of 1-year, successful adalimumab?. Digestive and Liver Disease Supplements, 2010, 4, 18-21.	0.2	0
98	Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: A case-control study. World Journal of Gastroenterology, 2010, 16, 4297.	3.3	92
99	Biologic targeting in the treatment of inflammatory bowel diseases. Biologics: Targets and Therapy, 2009, , 77.	3.2	35
100	An Analysis of the Factors Associated With the Development of Complications in Patients Undergoing Precut Sphincterotomy: A Prospective, Controlled, Randomized, Multicenter Study. American Journal of Gastroenterology, 2009, 104, 2412-2417.	0.4	70
101	Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis. American Journal of Gastroenterology, 2009, 104, 2089-2096.	0.4	223
102	HLA and Autoimmune Digestive Disease: A Clinically Oriented Review for Gastroenterologists. American Journal of Gastroenterology, 2009, 104, 195-217.	0.4	48
103	Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. American Journal of Gastroenterology, 2009, 104, 2760-2767.	0.4	114
104	Bowel Ultrasound and Mucosal Healing in Ulcerative Colitis. Digestive Diseases, 2009, 27, 285-290.	1.9	53
105	Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus. Endoscopy, 2009, 41, 618-637.	1.8	319
106	Use of double-balloon enteroscopy in the management of patients with Crohn's disease: feasibility and diagnostic yield in a high-volume centre for inflammatory bowel disease. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 2790-2795.	2.4	58
107	IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. Journal of Crohn's and Colitis, 2009, 3, 291-301.	1.3	20
108	Use of colonoscopy in the management of patients with Crohn's disease: Appropriateness and diagnostic yield. Digestive and Liver Disease, 2009, 41, 653-658.	0.9	3

#	Article	IF	Citations
109	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. American Journal of Gastroenterology, 2009, 104, 2483-2491.	0.4	37
110	Prospective Study of Long-Term Results and Prognostic Factors After Conservative Surgery for Small Bowel Crohn's Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 183-191.	4.4	52
111	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. European Journal of Gastroenterology and Hepatology, 2009, 21, 1036-1041.	1.6	42
112	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. World Journal of Gastroenterology, 2009, 15, 2469.	3.3	19
113	Biologic targeting in the treatment of inflammatory bowel diseases. Biologics: Targets and Therapy, 2009, 3, 77-97.	3.2	88
114	Prevalence of Pancreatic Insufficiency in Inflammatory Bowel Diseases. Assessment by Fecal Elastase-1. Digestive Diseases and Sciences, 2008, 53, 262-270.	2.3	51
115	Over-the-catheter precut to gain access to the biliary duct during ERCP rendezvous. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 2323-2325.	2.4	7
116	Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria. Inflammatory Bowel Diseases, 2008, 14, 812-818.	1.9	34
117	Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: A prospective study in an open access endoscopy service. Inflammatory Bowel Diseases, 2008, 14, 1133-1138.	1.9	18
118	Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn $\hat{E}\frac{1}{4}$ s disease. Inflammatory Bowel Diseases, 2008, 14, 1555-1561.	1.9	65
119	Extraintestinal manifestations of inflammatory bowel disease. Digestive and Liver Disease, 2008, 40, \$253-\$259.	0.9	171
120	Crohn's Disease: Achieving Patients' Benefits Paris, 27th October 2007. Digestive and Liver Disease Supplements, 2008, 2, 1-2.	0.2	0
121	Conventional drugs: the unmet needs. Digestive and Liver Disease Supplements, 2008, 2, 11-12.	0.2	0
122	Is it possible to modify the clinical course of Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 428-429.	1.7	1
123	Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1690.	7.4	236
124	Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut, 2008, 57, 211-217.	12.1	142
125	How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S238-S239.	1.9	4
126	Adalimumab for the treatment of Crohn's disease. Biologics: Targets and Therapy, 2008, 2, 763.	3.2	43

#	Article	IF	CITATIONS
127	Replication of interleukin 23 receptor and autophagyrelated 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World Journal of Gastroenterology, 2008, 14, 4643.	3.3	66
128	Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Core Evidence, 2008, 2, 209-29.	4.7	5
129	Sigmoid stricture in a 39-year-old female. Gut, 2007, 56, 1247-1247.	12.1	1
130	Association of NOD2/CARD15 mutations on Crohn??s disease phenotype in an Italian population. European Journal of Gastroenterology and Hepatology, 2007, 19, 217-223.	1.6	9
131	Transperineal Ultrasound in the Detection of Perianal and Rectovaginal Fistulae in Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 2214-2219.	0.4	90
132	Perianal Crohn's disease: Overview. Digestive and Liver Disease, 2007, 39, 957-958.	0.9	36
133	Imaging of perianal Crohn's disease. Digestive and Liver Disease, 2007, 39, 970-978.	0.9	28
134	Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointestinal Endoscopy, 2007, 65, 982-987.	1.0	64
135	Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 516-523.	1.9	38
136	Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study. Hepatology, 2007, 45, 1267-1274.	7.3	108
137	Review article: the management of steroid dependency in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2007, 26, 779-794.	3.7	55
138	New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. European Journal of Clinical Pharmacology, 2007, 63, 875-878.	1.9	24
139	Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: Long-awaited results?. Gastroenterology, 2006, 130, 607-608.	1.3	3
140	Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 55, 47-53.	12.1	446
141	Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid. Inflammatory Bowel Diseases, 2006, 12, 1007-1008.	1.9	12
142	Anorectal ultrasound for neoplastic and inflammatory lesions. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 113-135.	2.4	37
143	Sympathetic overactivity in active ulcerative colitis: effects of clonidine. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R224-R232.	1.8	83
144	Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Alimentary Pharmacology and Therapeutics, 2005, 22, 209-215.	3.7	42

#	Article	IF	CITATIONS
145	Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2005, 22, 453-461.	3.7	31
146	Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 348-349.	1.7	1
147	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.4	116
148	Patients with atherosclerosis may have increased circulating levels of 27â€hydroxycholesterol and cholestenoic acid. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 365-376.	1.2	63
149	Biologic Therapy for Inflammatory Bowel Disease. Drugs, 2005, 65, 2253-2286.	10.9	235
150	Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: Is no evidence of effect an evidence of no effect?. Gastroenterology, 2005, 128, 246-248.	1.3	2
151	Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Digestive and Liver Disease, 2005, 37, 407-417.	0.9	32
152	Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Digestive and Liver Disease, 2005, 37, 418-423.	0.9	69
153	Perianal Fistulae Following Infliximab Treatment. Inflammatory Bowel Diseases, 2004, 10, 91-96.	1.9	102
154	A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease1 1No competing interests declared Journal of the American College of Surgeons, 2004, 199, 8-20.	0.5	62
155	CASE REPORT: Ultrasonographic Detection of Toxic Megacolon in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2004, 49, 138-142.	2.3	22
156	The frame-shift mutation of the NOD2/CARD15 gene is significantly increased in ulcerative colitis: An â^—IG-IBD study. Gastroenterology, 2004, 126, 625-627.	1.3	26
157	Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology, 2004, 127, 730-740.	1.3	285
158	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. Digestive and Liver Disease, 2004, 36, 121-124.	0.9	31
159	Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Alimentary Pharmacology and Therapeutics, 2003, 18, 749-756.	3.7	111
160	Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Digestive and Liver Disease, 2003, 35, 619-627.	0.9	130
161	Infliximab-induced lupus in Crohn's disease: a case report. Digestive and Liver Disease, 2003, 35, 814-817.	0.9	58
162	Contrast Radiology, Computed Tomography and Ultrasonography in Detecting Internal Fistulas and Intra-Abdominal Abscesses in Crohn's Disease: A Prospective Comparative Study. American Journal of Gastroenterology, 2003, 98, 1545-1555.	0.4	181

#	Article	IF	Citations
163	Sonographic Prevalence of Liver Steatosis and Biliary Tract Stones in Patients with Inflammatory Bowel Disease: Study of 511 Subjects at a Single Center. Journal of Clinical Gastroenterology, 2003, 36, 417-420.	2.2	140
164	Infliximab in treatment of Crohn's disease: the Milan experience. Digestive and Liver Disease, 2002, 34, 411-418.	0.9	39
165	Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease, 2002, 34, 787-793.	0.9	37
166	Comparative Tolerability of Therapies for Ulcerative Colitis. Drug Safety, 2002, 25, 561-582.	3.2	32
167	Inflammatory bowel disease: new insights into pathogenesis and treatment. Journal of Internal Medicine, 2002, 252, 475-496.	6.0	153
168	Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. Journal of Internal Medicine, 2000, 247, 63-70.	6.0	173
169	The relationship between heritability and smoking habits in Crohn's disease. American Journal of Gastroenterology, 2000, 95, 3171-3175.	0.4	0
170	Is maintenance therapy always necessary for patients with ulcerative colitis in remission?. Alimentary Pharmacology and Therapeutics, 1999, 13, 373-379.	3.7	73
171	A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Alimentary Pharmacology and Therapeutics, 1999, 13, 381-388.	3.7	57
172	Ultrasonography in the Evaluation of Extension, Activity, and Follow-up of Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 1999, 34, 1103-1107.	1.5	90
173	Inflammatory bowel disease approaching the 3rd millennium pathogenesis and therapeutic implications?. European Journal of Gastroenterology and Hepatology, 1999, 11, 27-32.	1.6	27
174	Peptic ulcer therapy with cimetidine versus tripotassium dicitrato bismuthate in rheumatoid arthritis patients undergoing chronic NSAID treatment. Alimentary Pharmacology and Therapeutics, 1998, 12, 343-347.	3.7	3
175	A Practical Guide to the Management of Distal Ulcerative Colitis. Drugs, 1998, 55, 519-542.	10.9	42
176	Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. American Journal of Gastroenterology, 1998, 93, 799-803.	0.4	18
177	Guidelines for the treatment of ulcerative colitis in remission. European Journal of Gastroenterology and Hepatology, 1997, 9, 836-841.	1.6	16
178	Azathioprine in Steroid-Resistant and Steroid-Dependent Ulcerative Colitis. Journal of Clinical Gastroenterology, 1997, 25, 330-333.	2.2	102
179	The topical treatment of distal ulcerative colitis. European Journal of Gastroenterology and Hepatology, 1996, 8, 599-602.	1.6	10
180	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology, 1995, 108, 345-349.	1.3	197

#	Article	IF	CITATIONS
181	Sulglycotide in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastroduodenal Mucosal Injury: A Controlled Double-Blind, Double-Dummy, Randomized Endoscopic Study versus Placebo in Rheumatic Patients. Scandinavian Journal of Gastroenterology, 1993, 28, 875-878.	1.5	11
182	Endoscopic Assessment of Tenoxicam- and Piroxicam-Induced Lesions in Osteoarthritic Patients. Drug Investigation, 1991, 3, 53-56.	0.6	3
183	Cyclosporin treatment for severe active ulcerative colitis. Lancet, The, 1990, 336, 439.	13.7	22
184	Salsalate in the Treatment of Rheumatoid Arthritis: A Double-Blind Clinical and Gastroscopic Trial versus Piroxicam. Il – Endoscopic Evaluation. Journal of International Medical Research, 1989, 17, 320-323.	1.0	9
185	Effect of Esaprazole on Gastric Mucosal Potential Difference after Oral Administration of Aspirin (ASA). Journal of International Medical Research, 1986, 14, 321-324.	1.0	1
186	The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial. Journal of International Medical Research, 1985, 13, 332-337.	1.0	4